UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934



Date of Report (Date of earliest event reported):    January 30, 2007
                                                 -------------------------------

                              POSSIS MEDICAL, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          Minnesota                  0-944                  41-0783184
- --------------------------------------------------------------------------------
 (State or other jurisdiction     (Commission             (IRS Employer
      of incorporation)           File Number)          Identification No.)



9055 Evergreen Boulevard NW, Minneapolis, MN                 55433-8003
- --------------------------------------------------------------------------------
 (Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code   763-780-4555
                                                  ------------------------------

                                 Not Applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))




         Item 7.01 - Regulation FD Disclosure

         On January 30, 2007, Possis Medical, Inc., announced that it has
         received approval from the U.S. Food and Drug Administration (FDA) to
         market its AngioJet(R) Spiroflex(R) rapid exchange catheter to remove
         blood clots (thrombus) from coronary arteries. A copy of the press
         release is furnished as Exhibit 99.1 to this Report.

         Item 9.01 - Financial Statements and Exhibits

         [c]    Exhibits

         99.1   Press Release, dated January 30, 2007, issued by Possis Medical,
                Inc.



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Possis Medical, Inc.
- --------------------
(Registrant)

Date: January 30, 2007
      ----------------

By:   /s/ Jules L. Fisher
   -------------------------------------------------
      Jules L. Fisher
      Vice President, Finance and Chief Financial Officer






                                  EXHIBIT INDEX

Exhibit No.        Description
- -----------        -----------

99.1               Press Release, dated January 30, 2007, issued by Possis
                   Medical, Inc.